Sage Journals: Discover world-class research

Abstract

Doxorubicin is an effective anti-neoplastic agent; the reported toxicities of DOX limit its use. Luteolin is a polyphenolic phytochemical that exhibits beneficial biological effects via several mechanisms. We investigate luteolin protective effects on hepatorenal toxicity associated with doxorubicin treatment in rats. For 2 weeks, randomly assigned rat cohorts were treated as follows: control, luteolin (100 mg/kg; per os), doxorubicin alone (2mg/kg; by intraperitoneal injection), co-treated cohorts received luteolin (50 and 100 mg/kg) in addition to doxorubicin. Treatment with doxorubicin alone significantly (p < 0.05) increased biomarkers of hepatorenal toxicities in the serum. Doxorubicin also reduced relative organ weights, antioxidant capacity, and anti-inflammatory cytokine interleukine-10. Doxorubicin also increased reactive oxygen and nitrogen species, lipid peroxidation, pro-inflammatory-interleukin-1β and tumour necrosis factor-α-cytokine, and apoptotic caspases-3 and -9). Morphological damage accompanied these biochemical alterations in the rat’s liver and kidney treated with doxorubicin alone. Luteolin co-treatment dose-dependently abated doxorubicin-mediated toxic responses, improved antioxidant capacity and interleukine-10 level. Luteolin reduced (p < 0.05) lipid peroxidation, caspases-3 and -9 activities and marginally improved rats’ survivability. Similarly, luteolin co-treated rats exhibited improvement in hepatorenal pathological lesions observed in rats treated with doxorubicin alone. In summary, luteolin co-treatment blocked doxorubicin-mediated hepatorenal injuries linked with pro-oxidative, inflammatory, and apoptotic mechanisms. Therefore, luteolin can act as a chemoprotective agent in abating toxicities associated with doxorubicin usage and improve its therapeutic efficacy.

Keywords

Doxorubicin luteolin hepatorenal toxicity oxidative stress antioxidant inflammation apoptosis and rat

Introduction

Doxorubicin (DOX), is an anthracycline glycoside antibiotic,¹ commonly prescribed against several tumours.^2,3 DOX exerts its anti-neoplastic activity by intercalating with the DNA double-helix, thus inhibiting nucleic acid and protein synthesis. DOX covalently bind proteins necessary for DNA replication and transcription, thereby disrupting DNA replication and transcription,^4,5 and harming neoplastic cells. Cytochrome P₄₅₀ reductase metabolizes DOX to a semi-quinone radical that generates reactive oxygen species (ROS),^6,7 and increases its toxicity, inducing calcium overload mitochondrial dysfunction.^8–10 Toxicity of DOX to non-target tissues includes hepatic, cardiac, haematologic, and reproductive organs,^11–14 and this often limits its therapeutic dosages.¹⁵ DOX has been observed to induce hepatocyte damage by cell cycle arrest,¹⁶ thus inhibiting the self-regeneration potential of the liver.¹⁷ RONS produced from DOX metabolism increases the propensity for lipid peroxidation, DNA damage, and decreases cellular thiols and vitamin E levels.^18,19 DOX reported side effects to include hepatoxicity and nephrotoxicity.^20,21 The presence of severe proteinuria,²² and glomerular capillary permeability²³ has also been reported. Furthermore, DOX interferes with mitochondrial function, leading to decreased mitochondrial complex I–IV activities and increased superoxide (O2^•−) levels,²⁴ thus triggering lipid peroxidation and depletion of cellular antioxidant.²⁵

Luteolin (LUT) – 2-[3,4-dihydroxyphenyl]-5,7-dihydroxy-4-chromenone – is a member of the flavonoid family present in fruits and vegetables.^26,27 LUT is reported to exhibit multiple pharmacological effects: cytoprotective,²⁸ neuroprotective,²⁹ antioxidative,³⁰ anti-inflammatory,²⁷ anti-apoptotic and anti-neoplastic activities^26,31 in several disease models. The efficacy of LUT to induce apoptosis in breast cancer cells³² and sensitize carcinoma cells to a chemotherapeutic agent by LUT-loaded phytosomes³³ has been reported. These prospects open up new avenues for research to improve treatment efficacy by mitigating drug-related toxicities. Therefore, we investigated the beneficial effect of LUT as a chemoprotective agent for preventing DOX-mediated toxicity in an in vivo model. We assessed oxidative stress biomarkers’, antioxidant enzyme activities, and inflammatory mediators’ levels alongside the liver and kidney histopathological examination to achieve these goals. To gain mechanistic insight on how LUT modulates DOX-induce hepatorenal dysfunction in rats. Finally, we further report LUT’s protective mechanisms in the rats’ hepatorenal system treated with DOX.

Materials and methods

Chemicals

Doxorubicin, epinephrine, glutathione (GSH), thiobarbituric acid (TBA), hydrogen peroxide (H₂O₂), 5,5-dithio-bis-2-nitrobenzoic acid (DTNB), Griess reagent, 1-chloro-2, 4-dinitrobenzene (CDNB), xanthine, trichloroacetic acid, bovine serum albumin (BSA), hydrogen peroxide (H₂O₂) was purchased from Sigma (St Louis, Missouri, USA). Monosodium dihydrogen phosphate, disodium hydrogen phosphate, sodium carbonate, sodium hydroxide, copper sulphate, potassium iodide, sodium–potassium tartrate, and sodium chloride were obtained from BDH Ltd. (Poole, Dorset, UK) and William Hopkins Ltd. (Birmingham, UK). Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transferase (γ-GT), lactate dehydrogenase (LDH), urea and creatinine kits were obtained from Randox™ Laboratories Ltd. (Ardmore, Crumlin, Co., Antrim, UK). Enzyme-Linked Immunosorbent Assay (ELISA) kits for the assessment of Interleukin-1β (IL-1β), interleukin-10 (IL-10), tumour necrosis factor-alpha (TNF-α), caspase-3 and caspase-9 were obtained from Elabscience Biotechnology Company (Beijing, China). All other chemicals used for these experiments are of analytical grade.

Animal model and experimental design

Sexually mature, healthy male Wistar rats (160 ± 5 g, n = 50) were obtained from the Experimental Laboratory animal house, Faculty of Basic Medical Sciences, University of Ibadan. Experimental rats were housed under natural photoperiod conditions (12/12-hour light-dark) in a well-ventilated rodent facility of the Department of Biochemistry, provided with rat pellets (Ladokun™ Feeds, Ibadan, Nigeria) and allowed free access to water. Rats were allowed to adapt (7 days) to their new environment preceding experimentation and adequately cared for as specified by ‘Guide for the Care and Use of Laboratory Animals’ published by the National Institute of Health. Also, testing was performed following the University of Ibadan Ethical Committee’s approval (UI-ACUREC/20/035) and following the United States National Academy of Sciences guidelines.

Experimental protocol

The doses of Doxorubicin (2 mg/kg) and Luteolin (50 and 100 mg/kg dissolved in corn oil) used in the current study were selected based on previously published data.^34–36 New stock solutions of DOX (2 mg/mL) and LUT (50 mg/mL) were prepared every other day for dosing experimental rats. Rats were randomly divided into five treatment groups (n = 10), and specific groups were treated with a single dose of DOX, every other day for 6 days by intraperitoneal injection (i.p.),^37,38 and with LUT per os (p.o.)^30,39 for 14 consecutive days³⁰ as follows:

Group I: Control – administered corn oil-vehicle – (2 ml/kg; p. o) alone.

Group II: treated with LUT dissolved in corn oil (100 mg/kg; p.o) alone.

Group III: treated with DOX (2mg/kg; i.p.).

Group IV: DOX + LUT₁: treated with (DOX: 2 mg/kg) and (LUT: 50 mg/kg; p.o.).

Group V: (DOX + LUT₂): treated with (DOX: 2 mg/kg) and (LUT: 100 mg/kg; p.o.).

Following the last treatment, on day 15, the rats were weighed. Blood was collected from the retro-orbital venous plexus into both plain and ethylenediaminetetraacetic acid (EDTA)-containing pre-labelled sample bottles, and the experimental rats humanely sacrificed by carbon dioxide (CO₂) asphyxiation and confirmed by cervical dislocation.^40,41 Subsequently, the clotted blood was centrifuged at 3000g for 10 minutes, 4°C to obtain the serum. The liver and kidney were immediately excised, weighed, and processed for biochemical and histological analyses. The serum samples were stored (−20°C) until required for specific biochemical analysis.

Assessment of biomarkers of liver and kidney function

Analysis of serum activities of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), γ-glutamyl transferase (γ-GT), and lactate dehydrogenase (LDH), as well as creatinine and urea levels, were performed using available commercial kits from Randox™ Laboratories Limited (UK).

Preparation of tissue homogenate and assessment of biomarkers of liver and kidney oxidative and nitrative stress

The experimental rats’ liver and kidney samples were homogenized in phosphate buffer (0.05 M; pH 7.4). The tissue homogenates were centrifuged at 12,000g for 15 min at 4°C to obtain the supernatant used to assess oxidative stress, inflammatory and apoptotic biomarkers. According to Lowry’s method,⁴² liver and kidney protein concentrations were evaluated, and total sulfhydryl group were estimated by Ellman’s method.⁴³ Reduced glutathione (GSH) was determined by Jollow protocol⁴⁴ while glutathione-S-transferase (GST), glutathione peroxidase (GPx) and superoxide dismutase (SOD) activities were determined as previously described and reported.^45–48 Catalase (CAT) activity was determined using H₂O₂ as substrate as previously described by Claiborne,⁴⁹ while xanthine oxidase (XO) was quantified following Bergmeyer method.⁵⁰ According to the previously reported method by Buege and Aust^51,52 lipid peroxidation was assessed and expressed as μmol MDA/mg protein.

Reactive oxygen and nitrogen species (RONS) detection

Liver and kidney RONS production was evaluated according to an established protocol based on the RONS-dependent oxidation of 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) to dichlorofluorescein (DCF).⁵³ Briefly, the reaction mixture (150 µL 0.1 M potassium phosphate buffer; 35 µL distilled water, 10 µL sample and 5 µL freshly prepared DCFH-DA was constituted with minimal exposure to air. Fluorescence emission of DCF produced from DCFH-DA oxidation was spectrophotometrically analysed (wavelengths: 488 nm excitation; 525 nm emission) for 10 min at 30 s intervals using a Spectra Max 384 multi-modal plate reader (Molecular Devices, San Jose, CA, USA). DCF produced was expressed as a percentage over control.

Assay for pro-inflammatory biomarkers

The liver and kidney nitric oxide (NO) level was assessed using Griess reagent according to the established protocol.⁵⁴ Briefly, the reaction mixture consisting of an equal volume of sample and Griess reagent was incubated for 15 min before the absorbance was evaluated at 540 nm. The level of NO was extrapolated from the standard curve and then expressed as Units/mg protein. Moreover, myeloperoxidase (MPO) activity was evaluated according to the method described by Granell et al.⁵⁵ Additionally, IL-1β, IL-10, and TNF-α levels were determined using commercially available ELISA Kits and a SpectraMax™ plate reader (Molecular Devices, CA, USA), as stated in the manufacturer’s manual.

Assay for biomarkers of apoptosis caspase 3 and 9 activities

Liver and kidney caspase-3 and 9 activities were evaluated using Enzyme-Linked Immunosorbent Assay (ELISA) Kits (Elabscience; Beijing, China) following the manufacturer’s instructions. The results were obtained using a SpectraMax™ M384 Multi-modal plate reader (Molecular Devices, San Jose, CA, USA). Before the start of each assay, all reagents were calibrated to room temperature of 25°C. Briefly, 100 µL of standard and specimen were pipetted into designated wells in the specific caspase 3 and 9 ELISA and incubated for 90 min at 37°C. After that, standards and samples were discarded, and 100 µL of biotinylated detection antibody working solution was added to probe specific well and incubated for 60 min at 37°C. The reagent was aspirated off and each well washed thrice with approximately 300 µL of the 1X wash buffer. 100 µL of HRP conjugated working solution was added to each well, incubated for 30 min at 37°C and each well washed five times with the wash buffer. Following the substrate reagent (90 μL) was added to each well, and incubated for another 15 min at 37°C. The reaction was quenched with 50 µL of the stop solution and gently mixed by swirling for 20 seconds. Subsequently, the absorbance was immediately read using a Molecular Devices multi-modal plate reader at 450 nm (Caspase-3 and -9). The results were extrapolated from the standard curve generated and expressed in ng/mL.

Histopathological examination of liver and kidney

Liver and kidney samples were fixed using 10% phosphate-buffered formalin for 3 days. The samples were embedded in paraffin after dehydration procedures. Microtome cut tissue sections (4–5μm), fixed on charged microscopic glass slides, were subsequently stained with haematoxylin and eosin (H&E).⁵⁶ The tissue histology slides were blinded and examined under a light microscope (Leica DM 500, Germany) by a pathologist. The histopathological aberrations were scored and reported accordingly. Representative images were captured with a digital camera (Leica ICC50 E, Germany) attached to the microscope. Table 1 depicts the findings of semi-quantitative evaluation of rats’ liver and kidney scored for pathological aberration as previously reported,^57–60 following DOX and LUT treatment. The scoring criteria are denoted as none (0); mild (1); mild-moderate (2); moderate (3); moderate to severe (4) and severe (5).⁶¹

Table 1.

The incidence of the pathological lesions in the rat liver and kidney following treatment with LUT and DOX for 14 consecutive days.

	Control	LUT	DOX	DOX + LUT₁	DOX + LUT₂
Liver
Congestion of vessels	0	0	4	2	1
Focal area of inflammation/necrosis	0	0	5	3	1
Fatty infiltration/Large vacuoles	0	0	3	2	1
Hepatic degeneration	0	0	4	2	1
Kidney
Congestion of vessels	0	0	4	1	1
Focal area of inflammation/necrosis	0	0	5	2	1
Fatty infiltration/Large vacuoles	0	0	4	1	1

DOX – doxorubicin: 2 mg/kg; LUT – luteolin: 50 and 100 mg/kg; n = 10. Absolute numbers indicate the severity of histological changes observed in the examined tissues-liver (see Figure 9) and kidney (see Figure 10). Scores: None (0); mild (1); mild-moderate (2); moderate (3); moderate to severe (4) and severe (5).

Statistical analysis

Data were analysed using the one-way analysis of variance (ANOVA) and the post hoc Tukey test (GraphPad Prism 5 Software, La Jolla, California, USA, www.graphpad.com) ascertain significant differences in the treatment groups. P values <0.05 were considered significant. The results were subsequently expressed as mean ± standard deviation (SD).

Results

Effect of luteolin on rat survival and relative organ weight of doxorubicin-treated rats

The impact of LUT on rat survival (Kaplan-Meyers) and percentage weight change are presented in Figures 1(a) and (b). LUT (50 and 100 mg/kg) improved survival of rats co-treated with DOX, while DOX only reduced rat survivability (Figure 1(a)). DOX alone significantly (p < 0.05) decreased the body weight gain of rats compared to other treatment groups (Figure 1(b)). In comparison to DOX alone, groups of rats that received both DOX and LUT (50 and 100 mg/kg) showed improvement in body weight change, with respective percentage weight loss of 8.34% (LUT 50 mg/kg) and 4.30% (LUT 100 mg/Kg). The cohort of rats treated with LUT 100 mg/kg weight change was increased (p < 0.05) compared to the DOX alone and the DOX+LUT 50 and 100 mg/kg groups. DOX alone resulted in decreases in liver and kidney weight compared to the untreated control and LUT alone groups (Table 2)

Figure 1.

Effect of luteolin on percentage survival (a), and percentage weight change (b) of doxorubicin-treated rats. DOX: 2 mg/kg, i.p.; LUT₁ (50 mg/kg, p.o.); LUT₂ (100 mg/kg). DOX: Doxorubicin; LUT: Luteolin; i.p.: interperitoneally: p.o: per os.

Table 2.

Body weight gain and relative organ – liver and kidney – weights of rats following treatment with LUT and DOX for 14 consecutive days.

	Control	LUT	DOX	DOX + LUT1	DOX + LUT2
Weight change (g)	27.90 ± 9.35	23.40 ± 12.70	−37.43 ± 9.41*	−15.40 ± 2.00**	−8.30 ± 8.98**
Liver weight (g)	5.58 ± 0.47	6.33 ± 0.72	5.23 ± 0.80	5.40 ± 0.52	6.00 ± 0.86
Kidney weight (g)	1.23 ± 0.08	1.37 ± 0.15	1.22 ± 0.13	1.03 ± 0.12**	1.13 ± 0.08
Relative liver weight (%)	2.87 ± 0.22	3.19 ± 0.42	3.35 ± 0.48	3.55 ± 0.37	3.86 ± 0.40**
Relative kidney weight (%)	0.63 ± 0.04	0.69 ± 0.08	0.78 ± 0.05*	0.68 ± 0.08	0.74 ± 0.12

Values are expressed as mean ± SD of 10 rats, *p < 0.05 versus untreated control; **p < 0.05 versus DOX alone. SD: standard deviation; LUT, luteolin; DOX, doxorubicin.

Luteolin improves liver and kidney toxicities in doxorubicin-treated rats

The effect of DOX on the serum liver and kidney function biomarkers in rats is presented in Figure 2. DOX treatment alone caused increases (p < 0.05) in liver transaminases (ALT, AST, ALP, GGT), lactate dehydrogenase (LDH), as well as markers of kidney function, urea and creatinine, in rat serum compared to the control. Alterations in liver and kidney functional biomarkers were reduced (p < 0.05) by LUT at 50 and 100 mg/kg. These observed LUT-mediated improvements are dose-dependent.

Figure 2.

Effect of luteolin on hepatic and renal function markers of doxorubicin-treated rats. DOX: 2 mg/kg, i.p.; LUT: 100 mg/kg, per os; LUT₁ (50 mg/kg); LUT₂ (100 mg/kg). Each bar represents the mean ± SD of 10 rats. Connecting lines indicate groups compared to one another, the significance level was set at (p < 0.05); * to ****: indicates the level of significance; ns: not significant. DOX: doxorubicin; LUT: luteolin; SD: standard deviation. ALP: alkaline phosphatase; AST: aspartate amino transferase; ALT: alanine amino transferase; GGT: gamma-glutamyl transferase; LDH: lactate dehydrogenase.

Luteolin abates doxorubicin-induced hepatic and renal oxidative damage in rats

The protective effect of LUT against DOX-induced toxicities in rats’ liver and kidney is presented in Figures 3 –5. DOX alone increased (p < 0.05) liver and kidney activities of GPx and GST, and reduced (p < 0.05) GSH level compared to control (Figure 3). Conversely, LUT (50 and 100 mg/kg) co-treatment reversed the observed changes. Relative to the control, DOX treatment caused a similar increase in liver and kidney CAT and SOD activities and reduced TSH levels (Figure 4) reversed by LUT co-treatment at 50 and 100 mg/kg. Additionally, DOX treatment alone increased (p < 0.05) the levels of MDA and RONS, and XO activity in the liver and kidney compared to the control (Figure 5). These increase in pro-oxidant levels of RONS, MDA, and the free radical generating enzyme activity, XO reduced (p < 0.05) following co-treatment with LUT at both 50 and 100 mg/kg. LUT alone did not alter the balance between antioxidants and RONS species in rat liver and kidney.

Figure 3.

Effect of luteolin on GSH-dependent enzyme activities and GSH level in the liver and kidney of doxorubicin-treated rats. DOX: 2 mg/kg, i.p.; LUT: 100 mg/kg, per os; LUT₁ (50 mg/kg); LUT₂ (100 mg/kg). Each bar represents the mean ± SD of 10 rats. Connecting lines indicate groups compared to one another, the significance level was set at (p < 0.05); * to ****: indicates the level of significance; ns: not significant. DOX: doxorubicin; LUT: luteolin; SD: standard deviation. GPx: glutathione peroxidase; GST: glutathione-S-transferase; GSH: glutathione.

Figure 4.

Effect of Luteolin on SOD and CAT activities and TSH level in the liver and kidney of doxorubicin-treated rats. DOX: 2 mg/kg, i.p.; LUT: 100 mg/kg, per os; LUT₁ (50 mg/kg); LUT₂ (100 mg/kg). Each bar represents the mean ± SD of 10 rats. Connecting lines indicate groups compared to one another, the significance level was set at (p < 0.05); * to ****: indicates the level of significance; ns: not significant. DOX: doxorubicin; LUT: luteolin; SD: standard deviation. SOD: superoxide dismutase; CAT: catalase; TSH: total sulfhydryl group.

Figure 5.

Effect of luteolin on levels of RONS and LPO and activity of XO in the liver and kidney of Doxorubicin-treated rats. DOX: 2 mg/kg, i.p.; LUT: 100 mg/kg, per os; LUT₁ (50 mg/kg); LUT₂ (100 mg/kg). Each bar represents the mean ± SD of 10 rats. Connecting lines indicate groups compared to one another, the significance level was set at (p < 0.05); * to ****: indicates the level of significance; ns: not significant. DOX: doxorubicin; LUT: luteolin; SD: standard deviation. RONS: reactive oxygen/nitrogen species; LPO: lipid peroxidation; XO: xanthine oxidase.

Luteolin reduces the doxorubicin-mediated increase in biomarkers of inflammation in the liver and kidney of rats

The effects of LUT against DOX-mediated increase in inflammatory biomarkers are presented in Figures 6 and 7. DOX treatment alone increased (p < 0.05) MPO activity and NO level in rat liver and kidney compared to control (Figure 6). These were reduced (p < 0.05) in the presence of LUT at 50 and 100 mg/kg. Furthermore, DOX alone caused increases (p < 0.05) in pro-inflammatory: TNF-α, and IL-1β, and decreased (p < 0.05) anti-inflammatory IL-10, in rat’s liver and kidney compared to control (Figure 7). The observed changes were reversed in the presence of LUT, and more so at LUT 100mg/kg; by significantly decreasing TNF-α, and IL-1β and increasing IL-10.

Figure 6.

Effect of luteolin on NO level and MPO activity in the liver and kidney of doxorubicin-treated rats. DOX: 2 mg/kg, i.p.; LUT: 100 mg/kg, per os; LUT₁ (50 mg/kg); LUT₂ (100 mg/kg). Each bar represents the mean ± SD of 10 rats. Connecting lines indicate groups compared to one another, the significance level was set at (p < 0.05); * to ****: indicates the level of significance; ns: not significant. DOX: doxorubicin; LUT: luteolin; SD: standard deviation; NO: nitric oxide; MPO: myeloperoxidase.

Figure 7.

Effect of luteolin on TNF-α, IL-1β and IL-10 levels in the liver and kidney of doxorubicin-treated rats. DOX: 2 mg/kg, i.p.; LUT: 100 mg/kg, per os; LUT₁ (50 mg/kg); LUT₂ (100 mg/kg). Each bar represents the mean ± SD of 10 rats. Connecting lines indicate groups compared to one another, the significance level was set at (p < 0.05); * to ****: indicates the level of significance; ns: not significant. DOX: doxorubicin; LUT: luteolin; SD: standard deviation; TNF-α: tumour necrosis factor-alpha; IL1β: interleukin-1beta; IL-10: interleukin-10.

Luteolin attenuates the doxorubicin-mediated increase in apoptosis in rat liver and kidney

DOX treatment alone caused increases (p < 0.05) in the activities of initiator Caspase-9 (Casp-9) and executioner Caspase-3 (Casp-3) in treated rats’ liver and kidney compared to control (Figure 8). However, groups co-treated with LUT (50 and 100 mg/kg) caused reduction of DOX-mediated increase in Casp-9 and -3 activities in rats’ liver and kidney.

Figure 8.

Effect of luteolin on Caspase-3 and Caspase-9 activities in the liver and kidney of doxorubicin-treated rats. DOX: 2 mg/kg, i.p.; LUT: 100 mg/kg, per os; LUT₁ (50mg/kg); LUT₂ (100mg/kg). Each bar represents the mean ± SD of 10 rats. Connecting lines indicate groups compared to one another, the significance level was set at (p < 0.05); * to ****: indicates the level of significance; ns: not significant. DOX: doxorubicin; LUT: luteolin; SD: standard deviation.

Luteolin abated histopathological lesions in rat’s liver and kidney following treatment with doxorubicin

Photomicrographs of liver and kidney from rats treated with DOX and LUT were combined from microscopic examination and digital camera capture. Liver: Control and LUT treated rats consistently displayed typical liver morphology and histological-architecture. DOX alone showed marked disseminated congestion of veins and sinusoids infiltrated by inflammatory cells (black arrow), and disseminated microvascular steatosis. Sections from the DOX + LUT50 mg/kg group showed mild congestion of veins and sinusoids, and mild disseminated microvascular steatosis. In contrast, those from the DOX + LUT100 mg/kg group revealed mild disseminated congestion of veins and sinusoids and mild disseminated infiltration (Figure 9). Kidney: Control and LUT alone rats showed typical kidney morphology with no significant lesions. Treatment with DOX alone resulted in moderate disseminated congestion and glomerular hypercellularity/congestion of the kidney. DOX and LUT (50 and 100 mg/kg) decreased the observed changes and improved kidney cyto-architecture similar to typical histology features. The kidney sections from the DOX + LUT 50 mg/kg group showed mild glomerular hypercellularity/congestion. In contrast, those from rats in the DOX + LUT 100 mg/kg group are relatively more similar to the control, and LUT alone treated groups (Figure 10).

Figure 9.

The liver’s representative photomicrographs from control, LUT alone, DOX alone, and co-exposed (DOX+LUT) experimental rats. Control and LUT alone show no significant lesion, characterized by structural and functionally normal hepatocytes. Hepatic structure of rats treated with DOX alone presented with congested veins and sinusoids (black arrows), and the incidence of small-sized cytoplasmic vacuoles. The morphological attributes of the liver treated with DOX + LUT appeared to be improving dependent on the doses of LUT (LUT2 > LUT1), with lesser congestion (black arrow), mild disseminated congestion of sinusoids and infiltration by inflammatory cells. H and E stained, Magnification ×400: top panel; ×100: lower panel. DOX: doxorubicin; LUT: luteolin; LUT₁ (50 mg/kg); LUT₂ (100 mg/kg).

Figure 10.

Representative photomicrographs of the kidney from control, LUT alone, DOX alone, and co-exposed (DOX + LUT) experimental rats. Control and LUT groups showed no significant lesion. DOX showed mild to moderate disseminated congestion and glomerular hypercellularity/congestion (black arrows). DOX + LUT1 showed mild glomerular hypercellularity/congestion (black arrows). The histology of DOX + LUT2 appears similar to that of the control and LUT alone treated groups. H and E stained, Magnification ×400: top panel; ×100: lower panel. DOX: doxorubicin; LUT: luteolin; LUT₁ (50 mg/kg); LUT₂ (100 mg/kg).

Discussion

DOX is an active anti-neoplastic agent, limited in use by its associated hepatorenal toxicity.^7,17 We explore opportunities to improve DOX usage by devising strategies to mitigate DOX toxicity. These include compromised antioxidant defences due to oxidative stress, RONS generation, inflammatory, and apoptotic responses.⁶² Strategies focused on preventing DOX-induced toxicity include the use of chemopreventive agents,^63,64 such as plant-derived flavonoids. We hypothesized that LUT could be beneficial in attenuating drug-induced oxidative, inflammatory, and apoptotic responses in the rat hepatorenal system following DOX treatment. Our findings demonstrate that LUT lessened DOX-mediated hepatorenal dysfunction by abating tissue injury, oxido-inflammatory perturbation, and easing apoptotic cell death in rats. Our results show that DOX treatment resulted in a significant reduction of relative organ weight and rat survivability compared to control, consistent with a previous report.⁶⁵

The decrease in organ weight may be due in part to gastrointestinal toxicity, and reduced food consumption. The direct impact of DOX on renal tubules may prompt improper sodium excretion, and decrease water reabsorption, leading to polyuria, dehydration, and reduced body weight.^66,67 In contrast, improved relative organ weight and survivability were observed in LUT and DOX co-treated rats in our study. DOX alone increased hepatic transaminases in the serum, useful in diagnosing hepatic toxicity and necrotic damage,^68,69 supporting previous reports.^6,63 Co-administration of LUT dose-dependently decreased serum transaminase (ALT, ALP, LDH, GGT) levels indicates the protective role of LUT. Kidney function can be diagnosed from the byproducts of protein metabolism (urea) and a product from creatinine phosphate breakdown (creatinine). However, creatinine is a more accurate predictor of kidney injury than urea. Both the liver and kidney must be functioning correctly for the body to maintain a healthy level of urea.^70,71 DOX alters renal functions, and can significantly increase serum urea and creatinine levels.^7,62 LUT co-administration reduced serum urea and creatinine levels, indicative of the chemoprotective effect of LUT, a deduction supported by previous reports.^72,73

Oxidative stress results from an imbalance among antioxidants and pro-oxidants favouring pro-oxidants that can harm cells.⁷⁴ Oxidative stress-derived free radicals can overwhelm cellular enzymatic and non-enzymatic antioxidant defences. Consequently, damage macromolecules, worsen lipid peroxidation and increase further RONS production.⁵³ Increased RONS production further contributes to the initiation and progression of injuries and various hepatorenal system disorders.^9,65 Increase in RONS, LPO levels, and XO activity typically occurs with waning enzymatic antioxidant (SOD, CAT, GPx, GST) activities and GSH and TSH levels.⁷⁵ Data from our study shows that DOX alone caused an apparent decrease in hepatorenal antioxidant enzyme activities, GSH and TSH levels, as well as increases in LPO, RONS levels, and XO activity. DOX-induced oxidative stress can result in injuries to the hepatorenal system. LUT co-treated rats showed significant improvement in enzymatic antioxidant activities (SOD, CAT, GPx, GST) and GSH and TSH levels.

Similarly, LPO, and RONS levels and XO activity were reduced in rat’s cohort co-treated with LUT. These findings further emphasize the chemoprotective role of LUT on the rat hepatorenal system treated with DOX, consistent with earlier reports demonstrating the LUT protective effect in mice with acute renal injury⁷² and rats with liver injury.⁷⁶ The observed effects of LUT can be attributed to its inherent antioxidant activities.^77,78 MPO, NO, IL-1β, IL-10, and TNF-α play important inflammatory/pathological roles in several disorders and DOX-induced hepatorenal injuries.⁷⁰ LUT is reported to suppress oxido-inflammatory stress via the upregulation of the Nrf2/ARE/HO-1 signalling pathways.⁷⁹ The controlled release of MPO at the site of infection is of prime importance for its efficient use. However, any uncontrolled degranulation worsens inflammation and can cause tissue damage.⁸⁰ The combined roles of IL-1β, IL-10, and TNF-α in inflammatory processes have long been reported as they are known to recruit cells at the site of tissue injuries.⁸¹ The increases in liver and kidney levels of IL-1β and TNF-α, as well as a decrease in IL-10 in DOX treated rats, indicate an inflammatory response. Increases in IL-1β and TNF-α and the associated reduction of IL-10 levels can trigger inducible nitric oxide synthase (iNOS) to produce nitric oxide.

Subsequently, nitric oxide can combine with superoxide anion to form peroxynitrite, a harmful reactive nitrogen species.⁸² DOX administration triggers inflammatory-mediated actions by markedly increasing MPO activity and NO, IL-1β, TNF-α levels, and decreasing IL-10 levels in our study’s rat hepatorenal system. Our findings agree with previously published data on the DOX-mediated alteration of inflammation biomarkers.^83,84 The observed increases in hepatorenal MPO activity, NO, IL-1β and TNF-α levels, together with decreases in the level of IL-10 in DOX treated rats, may contribute to hepatorenal damage by inducing inflammatory and nitrosative stress. Conversely, decreases in MPO activity, NO, IL-1β, and TNF-α levels accompanying an increase in IL-10 level in rats co-treated with LUT and DOX demonstrated the alleviating effects of LUT on DOX-mediated inflammatory responses. As earlier previously reported, LUT exhibits anti-inflammatory properties.^27,85

Several apoptotic responses, including the intrinsic mitochondrial-dependent and extrinsic signalling pathways, have been implicated in the induction of programmed cell death. Signal transduction either through the intrinsic apoptotic molecules like Bax or extrinsic apoptotic molecules like Fas activate caspases, cysteine-dependent aspartate-specific proteases^86,87 including Casp-9, Casp-3, the initiator and executioner caspases respectively. A marked increase in the hepatorenal Casp-9 and Casp-3 activities in DOX alone treated rats connotes apoptosis activation in the present study. This observation is in line with earlier findings on the ability of DOX to induce apoptosis in mice and rats.^10,13 The observed reduction of Casp-9 and Casp-3 activities in rats co-treated with LUT signifies the suppression of apoptosis, due to the mitigating effect of LUT. Our findings support the previous report that LUT delayed apoptosis in an H₂O₂-induced ischaemic cerebrovascular disease model.⁸⁸ The histopathological examination appraises tissue integrity and disease progression and corroborates biochemical assays’ findings in serum and tissue enzyme assays. In this study, photomicrographs from the liver of rats administered with DOX alone showed marked disseminated congestion of veins and sinusoids compared to the liver sections from the control. LUT alone treated rats were found to be without significant lesions, hence corroborating our biochemical findings. Co-administration of LUT and DOX revealed mild congestion of veins and sinusoids, mild disseminated microvascular steatosis compared with the DOX alone treated group. These findings show that co-administration of LUT can protect the liver against DOX-mediated toxicity. The kidney photomicrographs revealed a similar pattern of DOX-induced toxicity, as previously reported on the nephrotoxic potentials of DOX in a rat model.⁷ Similarly, co-administration of LUT in the presence of DOX showed non-significant lesions compared with the DOX alone treated group. The nephroprotective effect of LUT has been reported in bisphenol A (BPA)-induced renal toxicity in rats,⁷⁹ owing to its additional antioxidant activity.⁸⁹

Conclusion

DOX elicits hepatorenal toxicity via oxidative stress, inflammation, and apoptotic cell damage, thereby limiting the therapeutic uses of DOX. Co-administration of LUT, dose-dependently reduced hepatorenal toxicities observed in rats treated with DOX alone. LUT co-treatment improved the antioxidant status and anti-inflammatory cytokine levels in experimental rats. LUT also suppressed pro-inflammatory cytokines production and the actions of Casp-3 and -9 involved in apoptosis as depicted in Figure 11. The combined administration of DOX and LUT may help improve the therapeutic efficacies of DOX by reducing the intolerable side effects observed in the patient when well-coordinated.

Figure 11.

Proposed mechanism of LUT in abating doxorubicin-induced hepatorenal toxicities in rats. Note that Cytochrome P450 reductase (CYP), carbonyl reductase (CBR) and aldo/keto reductase (A/KR) mediated the production of doxorubicinol. This toxic intermediate mediates oxidative stress, inflammation and apoptosis via the generation of ROS, RNS, IL-1β; and TNF-α; caspase-8 and -3. LUT abrogated these biochemical perturbations.

Footnotes

Acknowledgement

The authors would like to acknowledge Mr Eric Sabo’s technical assistance of the Department of Biochemistry, University of Ibadan.

Author contributions

All authors partook in the design, interpretation, analysis of the data generated from the study. SEO, UOA, and DOL conceptualized the experiments; carried out the research and preliminary data analysis. SEO and UOA supervised the investigation. SEO checked the generated data for error. The manuscript was written and revised by SEO, UOA.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

SE Owumi

References

Pang

Qiao

Janssen

, et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun 2013; 4: 1908.

Mantawy

El-Bakly

Esmat

, et al. Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation, and apoptosis. Eur J Pharmacol 2014; 728: 107–118.

Zhao

, et al. Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation. Biomed Pharmacother 2021; 137: 111308.

Swift

Rephaeli

Nudelman

, et al. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 2006; 66: 4863–4872.

Ashley

Poulton

. Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. Biochem Biophys Res Commun 2009; 378: 450–455.

Omobowale

Oyagbemi

Ajufo

, et al. Ameliorative effect of gallic acid in doxorubicin-induced hepatotoxicity in Wistar rats through antioxidant defense system. J Diet Suppl 2018; 15: 183–196.

Molehin

Adeyanju

Adefegha

, et al. Protective mechanisms of protocatechuic acid against doxorubicin-induced nephrotoxicity in rat model. J Basic Clin Physiol Pharmacol 2019; 30: 1–10.

Forrest

Swift

Rephaeli

, et al. Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation. Biochem Pharmacol 2012; 83: 1602–1612.

Abo-Salem

. The protective effect of aminoguanidine on doxorubicin-induced nephropathy in rats. J Biochem Mol Toxicol 2012; 26: 1–9.

10.

El-Moselhy

El-Sheikh

. Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity. Biomed Pharmacother 2014; 68: 101–110.

11.

Zaletok

Gulua

Wicker

, et al. Green tea, red wine and lemon extracts reduce experimental tumor growth and cancer drug toxicity. Exp Oncol 2015; 37: 262–271.

12.

Dai

Wang

, et al. Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. Oncotarget 2015; 6: 17738–17752.

13.

Nagai

Oda

Konishi

. Theanine prevents doxorubicin-induced acute hepatotoxicity by reducing intrinsic apoptotic response. Food Chem Toxicol 2015; 78: 147–152.

14.

Kumral

Giris

Soluk-Tekkesin

, et al. Beneficial effects of carnosine and carnosine plus vitamin E treatments on doxorubicin-induced oxidative stress and cardiac, hepatic, and renal toxicity in rats. Hum Exp Toxicol 2016; 35: 635–643.

15.

Carvalho

Santos

Cardoso

, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009; 16: 3267–3285.

16.

Quiles

Huertas

Battino

, et al. Antioxidant nutrients and adriamycin toxicity. Toxicology 2002; 180: 79–95.

17.

Kassner

Huse

, et al. Carbonyl reductase 1 is a predominant DOXorubicin reductase in the human liver. Drug Metab Depos 2008; 36: 2113–2120.

18.

Kalender

Yel

Kalender

Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology 2005; 209: 39–45.

19.

Ortiz

Caja

Sancho

, et al. Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of DOXorubicin in rat hepatoma cells: role of reactive oxygen species production and glutathione depletion. Biochem Pharmacol 2008; 75: 1935–1945.

20.

Zheng

Pavlidis

Chua

, et al. An ancestral haplotype defines susceptibility to doxorubicin nephropathy in the laboratory mouse. J Am Soc Nephrol 2006; 17: 1796–1800.

21.

Liu

Qiu

Liu

, et al. Citronellal ameliorates doxorubicin-induced hepatotoxicity via antioxidative stress, antiapoptosis, and proangiogenesis in rats. J Biochem Mol Toxicol 2021; 35: e22639.

22.

Lebrecht

Setzer

Rohrbach

, et al. Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis. Nephrol Dial Transplant 2004; 19: 329–336.

23.

Wang

Tay

, et al. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 2000; 58: 1797–1804.

24.

Ozen

Usta

Sahin-erdemli

, et al. Nephrology dialysis transplantation association of nitric oxide production and apoptosis in a model of experimental nephropathy. Nephrol Dial Transplant 2001; 16: 32–38.

25.

Kockar

Naziroglu

Celik

, et al. N-acetylcysteine modulates doxorubicin-induced oxidative stress and antioxidant vitamin concentrations in liver of rats. Cell Biochem Funct 2010; 28: 673–677.

26.

Cook

. Mechanism of metastasis suppression by luteolin in breast cancer. Breast Cancer (Dove Med Press) 2018; 10: 89–100.

27.

Kwon

Choi

. Luteolin Targets the toll-like receptor signaling pathway in prevention of hepatic and adipocyte fibrosis and insulin resistance in diet-induced obese mice. Nutrients 2018; 10: 1–17.

28.

Psotova

Chlopcikova

Miketova

, et al. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part III. Apigenin, baicalelin, kaempherol, luteolin and quercetin. Phytother Res 2004; 18: 516–521.

29.

Tan

Yang

, et al. Luteolin exerts neuroprotection via modulation of the p62/Keap1/Nrf2 pathway in intracerebral hemorrhage. Front Pharmacol 2020; 10: 1–15.

30.

Owumi

Ijadele

Arunsi

, et al. Luteolin abates reproductive toxicity mediated by the oxido-inflammatory response in doxorubicin-treated rats. Toxicol Res Appl 2020; 4: 1–16.

31.

Zhang

Ying

, et al. Decrease of AIM2 mediated by luteolin contributes to non-small cell lung cancer treatment. Cell Death Dis 2019; 10: 218.

32.

Ahmed

Khan

Fratantonio

, et al. Apoptosis induced by luteolin in breast cancer: mechanistic and therapeutic perspectives. Phytomedicine 2019; 59: 152883.

33.

Sabzichi

Hamishehkar

Ramezani

, et al. Luteolin-loaded phytosomes sensitize human breast carcinoma MDA-MB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling. Asian Pac J Cancer Prev 2014; 15: 5311–5316.

34.

Altinkayank

Kural

Akcan

, et al. Biomedicine & pharmacotherapy protective effects of L-theanine against doxorubicin-induced nephrotoxicity in rats. Biomed Pharmacother 2018; 108: 1524–1534.

35.

Jacevic

Dragojevic-Simic

Tatomirovi

, et al. The efficacy of amifostine against multiple-dose DOXorubicin-induced toxicity in rats. Int J Mol Sci 2018; 19: 1–18.

36.

Ahmed

Abtar

Othman

, et al. Effects of quercetin, sitagliptin alone or in combination in testicular toxicity induced by doxorubicin in rats. Drug Des Devel Ther 2019; 13: 3321–3329.

37.

Huyut

Alp

Yaman

, et al. Comparison of the protective effects of curcumin and caffeic acid phenethyl ester against doxorubicin-induced testicular toxicity. Andrologia 2020: e13919.

38.

Zhu

Jin

Ren

. Ulinastatin reduces myocardial injury induced by doxorubicin in SD rats. Eur Rev Med Pharmacol Sci 2020; 24: 10769–10778.

39.

Abu-Elsaad

El-Karef

. Protection against nonalcoholic steatohepatitis through targeting IL-18 and IL-1alpha by luteolin. Pharmacol Rep 2019; 71: 688–694.

40.

Hawkins

Prescott

Carbone

, et al. A good death? Report of the second Newcastle meeting on laboratory animal euthanasia. Animals (Basel) 2016; 6: 50.

41.

AVMA AVMA. 2000 Report of the AVMA Panel on Euthanasia. J Am Vet Med Assoc 2001; 218: 669–696.

42.

Lowry

Rosebrough

Farr

, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–275.

43.

Ellman

. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70–77.

44.

Jollow

Mitchell

Zampaglione

, et al. Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 1974; 11: 151–169.

45.

Habig

Pabst

Jakoby

. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249: 7130–7139.

46.

Rotruck

Pope

Ganther

, et al. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973; 179: 588–590.

47.

Misra

Fridovich

. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247: 3170–3175.

48.

Owumi

Dim

UJ.

Biochemical alterations in diclofenac-treated rats: effect of selenium on oxidative stress, inflammation, and hematological changes. Toxicol Res Appl 2019; 3: 1–10.

49.

Clairborne

. Catalase activity. Boca Raton, FL: CRC Press, 1995.

50.

Bergmeyer

Gawehn

Grassl

. Methods of enzymatic analysis. 2nd ed. New York, NY: Academic Press Inc, 1974.

51.

Buege

Aust

. Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302–310.

52.

Owumi

Olusola

Arunsi

, et al. Chlorogenic acid abates oxido-inflammatory and apoptotic responses in the liver and kidney of Tamoxifen-treated rats. Toxicology Research. Epub ahead of print 13 February 2021. DOI: 10.1093/toxres/tfab002.

53.

Owumi

Dim

. Manganese suppresses oxidative stress, inflammation and caspase-3 activation in rats exposed to chlorpyrifos. Toxicol Rep 2019; 6: 202–209.

54.

Green

Wagner

Glogowski

, et al. Analysis of nitrate, nitrite, and [15 N]nitrate in biological fluids. Anal Biochem 1982; 126: 131–138.

55.

Granell

Gironella

Bulbena

, et al. Heparin mobilizes xanthine oxidase and induces lung inflammation in acute pancreatitis. Crit Care Med 2003; 31: 525–530.

56.

Bancroft

Gamble

. Theory and practise of histological techniques. 6th ed. Philadelphia, PA: Churchill Livingstone Elsevier, 2008, pp. 83–134.

57.

Owumi

Najophe

. Dichloromethane and ethanol co-exposure aggravates oxidative stress indices causing hepatic and renal dysfunction in pubertal rats. Toxicol Res Appl 2019; 3: 1–10.

58.

Owumi

Aliyu-Banjo

Danso

. Fluoride and diethylnitrosamine coexposure enhances oxido-inflammatory responses and caspase-3 activation in liver and kidney of adult rats. J Biochem Mol Toxicol 2019; 33: e22327.

59.

Gibson-Corley

Olivier

Meyerholz

. Principles for valid histopathologic scoring in research. Vet Pathol 2013; 50: 1007–1015.

60.

Klopfleisch

. Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology – a systematic review. BMC Vet Res 2013; 9: 123.

61.

Owumi

Nwozo

Effiong

, et al. Gallic acid and omega-3 fatty acids decrease inflammatory and oxidative stress in manganese-treated rats. Exp Biol Med (Maywood) 2020; 245: 835–844.

62.

Kumral

Giris

Soluk-Tekkesin

, et al. Effect of olive leaf extract treatment on doxorubicin-induced cardiac, hepatic and renal toxicity in rats. Pathophysiology 2015; 22: 117–123.

63.

Akindele

Oludadepo

Amagon

, et al. Protective effect of carvedilol alone and coadministered with diltiazem and prednisolone on DOXorubicin and 5-fluorouracil-induced hepatotoxicity and nephrotoxicity in rats. Pharmacol Res Perspect 2018; 6: e00381.

64.

Cook

Liang

Besch-Williford

, et al. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. Breast Cancer (Dove Med Press) 2017; 9: 9–19.

65.

Afsar

Razak

Almajwal

Effect of Acacia hydaspica R. Parker extract on lipid peroxidation, antioxidant status, liver function test and histopathology in doxorubicin treated rats. Lipids Health Dis 2019; 18: 126.

66.

Zhang

Liu

, et al. Luteolin attenuates doxorubicin-induced cardiotoxicity by modulating the PHLPP1/AKT/Bcl-2 signalling pathway. PeerJ 2020; 8: e8845.

67.

Mathias

Alegre

PHC

Dos Santos

IOF

, et al. Euterpe oleracea Mart. (Acai) supplementation attenuates acute doxorubicin-induced cardiotoxicity in rats. Cell Physiol Biochem 2019; 53: 388–399.

68.

Loomba

Sanyal

Kowdley

, et al. Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis. Gastroenterology 2019; 156: 88–95.e5.

69.

Ramaiah

. A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters. Food Chem Toxicol 2007; 45: 1551–1557.

70.

Drago

Manea

Timofte

, et al. Mechanisms of herbal nephroprotection in diabetes mellitus. J Diabetes Res 2020; 2020: 1–31.

71.

Noce

Bocedi

Campo

, et al. A pilot study of a natural food supplement as new possible therapeutic approach in chronic kidney disease patients. Pharmaceuticals 2020; 13: 1–15.

72.

Xin

Yan

, et al. Protective effects of luteolin on lipopolysaccharide-induced acute renal injury in mice. Med Sci Monit 2016; 22: 5173–5180.

73.

Andres-Hernando

Cicerchi

, et al. Protective role of fructokinase blockade in the pathogenesis of acute kidney injury in mice. Nat Commun 2017; 8: 14181.

74.

Zhu

Bai

, et al. Histological changes, lipid metabolism, and oxidative and endoplasmic reticulum stress in the liver of laying hens exposed to cadmium concentrations. Poult Sci 2020; 99: 3215–3228.

75.

Owumi

Olayiwola

Alao

, et al. Cadmium and nickel co-exposure exacerbates genotoxicity and not oxido-inflammatory stress in liver and kidney of rats: protective role of omega-3 fatty acid. Environ Toxicol 2020; 35: 231–241.

76.

Lodhi

Vadnere

Patil

, et al. Protective effects of luteolin on injury-induced inflammation through reduction of tissue uric acid and pro-inflammatory cytokines in rats. J Tradit Complement Med 2020; 10: 60–69.

77.

Castellino

Nikolic

Magán-Fernández

, et al. Altilix® supplement containing chlorogenic acid and luteolin improved hepatic and cardiometabolic parameters in subjects with metabolic syndrome: a 6 month randomized, double-blind, placebo-controlled study. Nutrients 2019; 11: 1–17.

78.

Mhalla

Bouassida

Chawech

, et al. Antioxidant, hepatoprotective, and anti-depression effects of rumex tingitanus extracts and identification of a novel bioactive compound. Biomed Res Int 2018; 2018: 1–10.

79.

Alekhya-Sita

Gowthami

Srikanth

, et al. Protective role of luteolin against bisphenol A-induced renal toxicity through suppressing oxidative stress, inflammation, and upregulating Nrf2/ARE/HO-1 pathway. IUBMB Life 2019; 71: 1041–1047.

80.

Khan

Alsahli

Rahmani

. Myeloperoxidase as an active disease biomarker: recent biochemical and pathological perspectives. Med Sci 2018; 6: 1–21.

81.

Kany

Vollrath

Relja

. Cytokines in inflammatory disease. Int J Mol Sci 2019; 20: 1–31.

82.

Wali

Rashid

, et al. Naringenin regulates doxorubicin-induced liver dysfunction: impact on oxidative stress and inflammation. Plants (Basel) 2020; 9: 1–17.

83.

Cappetta

Angelis

, et al. Review article oxidative stress and cellular response to DOXorubicin: a common factor in the complex milieu of anthracycline cardiotoxicity. Oxid Med Cell Longev 2017; 2017: 1–13.

84.

Wang

Liu

, et al. Inhibition of TRPA1 attenuates doxorubicin-induced acute cardiotoxicity by suppressing oxidative stress, the inflammatory response, and endoplasmic reticulum stress. Oxid Med Cell Longev 2018; 2018: 5179468.

85.

Basu

Das

Majumder

, et al. Antiatherogenic roles of dietary flavonoids chrysin, quercetin, and luteolin. J Cardiovasc Pharmacol 2016; 68: 89–96.

86.

D’Arcy

. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int 2019; 43: 582–592.

87.

Yan

Elbadawi

Efferth

. Multiple cell death modalities and their key features (Review). World Acad Sci J 2020; 2: 39–48.

88.

Zhang

, et al. Luteolin protects PC-12 cells from H₂O₂-induced injury by up-regulation of microRNA-21. Biomed Pharmacother 2019; 112: 108698.

89.

Xiao

Xia

Wang

, et al. Luteolin attenuates cardiac ischemia/reperfusion injury in diabetic rats by modulating Nrf2 antioxidative function. Oxid Med Cell Longev 2019; 2019: 2719252.

Luteolin attenuates doxorubicin-induced derangements of liver and kidney by reducing oxidative and inflammatory stress to suppress apoptosis

Abstract

Keywords

Introduction

Materials and methods

Chemicals

Animal model and experimental design

Experimental protocol

Assessment of biomarkers of liver and kidney function

Preparation of tissue homogenate and assessment of biomarkers of liver and kidney oxidative and nitrative stress

Reactive oxygen and nitrogen species (RONS) detection

Assay for pro-inflammatory biomarkers

Assay for biomarkers of apoptosis caspase 3 and 9 activities

Histopathological examination of liver and kidney

Statistical analysis

Results

Effect of luteolin on rat survival and relative organ weight of doxorubicin-treated rats

Luteolin improves liver and kidney toxicities in doxorubicin-treated rats

Luteolin abates doxorubicin-induced hepatic and renal oxidative damage in rats

Luteolin reduces the doxorubicin-mediated increase in biomarkers of inflammation in the liver and kidney of rats

Luteolin attenuates the doxorubicin-mediated increase in apoptosis in rat liver and kidney

Luteolin abated histopathological lesions in rat’s liver and kidney following treatment with doxorubicin

Discussion

Conclusion

Footnotes

Acknowledgement

Author contributions

Declaration of conflicting interests

Funding

ORCID iD

References